Douglas G. McNeel, MD, PhD close
Douglas G. McNeel, MD, PhD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Douglas G. McNeel, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. McNeel is a genitourinary medical oncologist with a clinical and research focus on prostate cancer immunology. Since 1997 he and his laboratory have studied vaccines for prostate cancer, specifically identifying antigens to target in vaccines, testing the ability of vaccines to eliminate prostate cancer cells and translating these studies to human clinical trials.


Medical Oncology

Bladder Cancer

Genitourinary Cancer (Bladder, Kidney, Prostate, Testicular)

Kidney Cancer

Prostate Cancer

Testicular Cancer


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship Fred Hutchinson Cancer Research Center, Seattle, WA
University of Washington Medical Center, Seattle, WA
Residency University of Washington Medical Center, Seattle, WA
Internship University of Washington School of Medicine, Seattle, WA
Medical School University of Chicago, Pritzker School of Medicine, Chicago, IL

Languages Spoken

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
PubMed Articles
McNeel DG Eickhoff JC Johnson LE Roth AR Perk TG Fong L Antonarakis ES Wargowski E Jeraj R Liu G Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer. J Clin Oncol . 2019 Oct 23;:JCO1901701
[PubMed ID: 31644357]
Zahm CD Johnson LE McNeel DG Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy. Cancer Immunol Immunother . 2019 Oct;68(10):1661-1669
[PubMed ID: 31606777]
Ehlerding EB Lee HJ Barnhart TE Jiang D Kang L McNeel DG Engle JW Cai W Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with <sup>89</sup>Zr-Df-Atezolizumab. Bioconjug Chem . 2019 May 15;30(5):1434-1441
[PubMed ID: 30973703]
Scarpelli M Zahm C Perlman S McNeel DG Jeraj R Liu G FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. J Immunother Cancer . 2019 Jan 30;7(1):23
[PubMed ID: 30700328]
Ehlerding EB Lee HJ Jiang D Ferreira CA Zahm CD Huang P Engle JW McNeel DG Cai W Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. Am J Cancer Res . 2019;9(1):53-63
[PubMed ID: 30755811]
Zahm CD Colluru VT McIlwain SJ Ong IM McNeel DG TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8<sup>+</sup> T Cells. Cancer Immunol Res . 2018 Nov;6(11):1364-1374
[PubMed ID: 30201735]
McNeel DG Eickhoff JC Wargowski E Zahm C Staab MJ Straus J Liu G Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget . 2018 May 22;9(39):25586-25596
[PubMed ID: 29876010]
Johnson LE Brockstedt D Leong M Lauer P Theisen E Sauer JD McNeel DG Heterologous vaccination targeting prostatic acid phosphatase (PAP) using DNA and <i>Listeria</i> vaccines elicits superior anti-tumor immunity dependent on CD4+ T cells elicited by DNA priming. Oncoimmunology . 2018;7(8):e1456603
[PubMed ID: 30221049]
Miller JS Morishima C McNeel DG Patel MR Kohrt HEK Thompson JA Sondel PM Wakelee HA Disis ML Kaiser JC Cheever MA Streicher H Creekmore SP Waldmann TA Conlon KC A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. Clin Cancer Res . 2018 Apr 1;24(7):1525-1535
[PubMed ID: 29203590]
Wargowski E Johnson LE Eickhoff JC Delmastro L Staab MJ Liu G McNeel DG Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer . 2018 Mar 13;6(1):21
[PubMed ID: 29534736]
McNeel DG Therapeutic Cancer Vaccines: How Much Closer Are We? BioDrugs . 2018 Feb;32(1):1-7
[PubMed ID: 29285731]
England CG Jiang D Ehlerding EB Rekoske BT Ellison PA Hernandez R Barnhart TE McNeel DG Huang P Cai W <sup>89</sup>Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging . 2018 Jan;45(1):110-120
[PubMed ID: 28821924]
Kelly M McNeel D Fisch P Malkovsky M Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. Immunol Lett . 2018 Jan;193:1-10
[PubMed ID: 29129721]
Olson BM Gamat M Seliski J Sawicki T Jeffery J Ellis L Drake CG Weichert J McNeel DG Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. Cancer Immunol Res . 2017 Dec;5(12):1074-1085
[PubMed ID: 29051161]
Zahm CD Colluru VT McNeel DG Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8<sup>+</sup> T Cells. Cancer Immunol Res . 2017 Aug;5(8):630-641
[PubMed ID: 28634215]
Johnson LE Olson BM McNeel DG Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. J Immunother Cancer . 2017 Jul 18;5(1):56
[PubMed ID: 28716080]
Zahm CD Colluru VT McNeel DG DNA vaccines for prostate cancer. Pharmacol Ther . 2017 Jun;174:27-42
[PubMed ID: 28185916]
Ehlerding EB England CG Majewski RL Valdovinos HF Jiang D Liu G McNeel DG Nickles RJ Cai W ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer. Mol Pharm . 2017 May 1;14(5):1782-1789
[PubMed ID: 28388076]
Olson BM Bradley ES Sawicki T Zhong W Ranheim EA Bloom JE Colluru VT Johnson LE Rekoske BT Eickhoff JC McNeel DG Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD). Prostate . 2017 May;77(7):812-821
[PubMed ID: 28181678]
England CG Ehlerding EB Hernandez R Rekoske BT Graves SA Sun H Liu G McNeel DG Barnhart TE Cai W Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med . 2017 Jan;58(1):162-168
[PubMed ID: 27493273]